NCT02087813

Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses

A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Neuromyelitis Optica (NMO) is a rare, devastating demyelinating disease of the central nervous system (CNS) that has different causes and treatments from the more common demyelinating disease multiple sclerosis (MS). Current NMO therapies are nonspecific and have varying and often suboptimal benefit. The investigators will evaluate whether use of alpha1-antitrypsin (A1AT, an FDA-approved medication for patients with congenital deficiency of A1AT associated with emphysema) can benefit acute attacks of NMO, improving patient disability and quality of life.

Conditions

• Neuromyelitis Optica

Interventions

Type	Name	Description
DRUG	Alpha1-antitrypsin
DRUG	methylprednisolone	3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.

Timeline

• Start date: 2014-03-01
• Primary completion: 2016-03-01
• First posted: 2014-03-14
• Last updated: 2019-04-12

Locations

1 site across 1 country: United States